Physician profile
Robert D Millar
NPI 1073507935
$3,630.61
in general payments reported to CMS, 2019-2025
24 companies · $2,778 in 2025
The $2,778 reported for 2025 was more than what 87% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $16.68 · 2021: $315 · 2022: $71.93 · 2023: $275 · 2025: $2,778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,052.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,052.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aop Health US, LLC | $1,967.34 | 2025 | Rapiblyk |
| Lantheus Medical Imaging, INC. | $650.91 | 2019-2023 | Definity |
| Boston Scientific Corporation | $131.96 | 2025 | General - Therapies, Bodyguardian |
| Astrazeneca Pharmaceuticals LP | $96.85 | 2025 | Wainua, Lokelma |
| Edwards Lifesciences Corporation | $93.44 | 2025 | |
| Bridgebio Pharma, INC. | $85.79 | 2025 | Attruby |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $83.89 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $63.32 | 2019-2025 | Eliquis, Camzyos |
| Scpharmaceuticals INC. | $54.60 | 2025 | |
| Abbott Laboratories | $51.92 | 2025 | Navitor |
| Janssen Pharmaceuticals, INC | $49.68 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.88 | 2025 | |
| Pfizer INC. | $33.76 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $30.94 | 2025 | Opsumit, Uptravi |
| Cvrx, INC. | $29.00 | 2025 | Barostim Neo System |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $25.99 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Philips North America LLC | $22.89 | 2022 | |
| Novartis Pharmaceuticals Corporation | $21.02 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $18.50 | 2023 | Arcalyst |
| Chiesi USA, INC. | $17.95 | 2025 | Juxtapid |
| Merck Sharp & Dohme LLC | $16.94 | 2025 | Verquvo |
| Glaxosmithkline, LLC. | $16.64 | 2025 | Shingrix, Arexvy |
| Medtronic, INC. | $14.82 | 2025 | Linq II |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.58 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Millar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.